These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27468625)

  • 1. Public participation in decision-making on the coverage of new antivirals for hepatitis C.
    Kieslich K; Ahn J; Badano G; Chalkidou K; Cubillos L; Hauegen RC; Henshall C; Krubiner CB; Littlejohns P; Lu L; Pearson SD; Rid A; Whitty JA; Wilson J
    J Health Organ Manag; 2016 Aug; 30(5):769-85. PubMed ID: 27468625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.
    Ho H; Janjua NZ; McGrail KM; Harrison M; ; Law MR
    PLoS One; 2021; 16(3):e0247843. PubMed ID: 33647068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wales approves new hepatitis C drug while England deliberates.
    Ozieranski P; King L
    BMJ; 2016 Dec; 355():i6499. PubMed ID: 27908876
    [No Abstract]   [Full Text] [Related]  

  • 4. Compulsory licences for direct acting antiviral drugs for hepatitis C.
    Cattaneo A; Maciocco G
    BMJ; 2016 Oct; 355():i5314. PubMed ID: 27707734
    [No Abstract]   [Full Text] [Related]  

  • 5. Role Of Generics In Treatment Of Hepatitis C Infection.
    Umar M; Akhter TS; Akbar I; Nisar G; Osama M; Akhter TS
    J Ayub Med Coll Abbottabad; 2016; 28(4 Suppl 1):S890-S894. PubMed ID: 28782339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction: priority setting, equitable access and public involvement in health care.
    Weale A; Kieslich K; Littlejohns P; Tugendhaft A; Tumilty E; Weerasuriya K; Whitty JA
    J Health Organ Manag; 2016 Aug; 30(5):736-50. PubMed ID: 27468772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brazil's Fight against Hepatitis C - Universalism, Local Production, and Patents.
    da Fonseca EM; Shadlen K; Bastos FI
    N Engl J Med; 2019 Feb; 380(7):605-607. PubMed ID: 30763192
    [No Abstract]   [Full Text] [Related]  

  • 8. Indian hepatitis C drug patent decision shakes public health community.
    't Hoen EFM
    Lancet; 2016 Jun; 387(10035):2272-2273. PubMed ID: 27238944
    [No Abstract]   [Full Text] [Related]  

  • 9. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics.
    Liao JM; Fischer MA
    Am J Public Health; 2017 Jun; 107(6):893-899. PubMed ID: 28426313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs.
    Clément V; Raimond V
    Value Health; 2019 Feb; 22(2):220-224. PubMed ID: 30711067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
    Hundemer GL; Sise ME; Wisocky J; Ufere N; Friedman LS; Corey KE; Chung RT
    Infect Dis (Lond); 2015; 47(12):924-9. PubMed ID: 26365684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study.
    Geenen JW; Boersma C; Klungel OH; Hövels AM
    Eur J Health Econ; 2019 Aug; 20(6):857-867. PubMed ID: 30953216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
    Chhatwal J; Kanwal F; Roberts MS; Dunn MA
    Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptive rationing: reflections and suggestions for priority setters in health care.
    Williams I
    J Health Organ Manag; 2015; 29(6):701-10. PubMed ID: 26394253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the role of sofosbuvir in treating hepatitis C infection?
    Carey L
    JAAPA; 2015 Feb; 28(2):16-9. PubMed ID: 25621961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.
    Johnson SW; Davis MM; Stever LM; Priest DH
    J Clin Pharm Ther; 2016 Dec; 41(6):727-729. PubMed ID: 27670742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why orphan drug coverage reimbursement decision-making needs patient and public involvement.
    Douglas CM; Wilcox E; Burgess M; Lynd LD
    Health Policy; 2015 May; 119(5):588-96. PubMed ID: 25641123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the role of contextual influences on local health-care decision making: case study results from Ontario, Canada.
    Abelson J
    Soc Sci Med; 2001 Sep; 53(6):777-93. PubMed ID: 11511053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.